U.S. Markets open in 6 hrs 18 mins

Biohaven Announces Proposed Public Offering Of Common Shares

NEW HAVEN, Conn., June 17, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $300 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven.  In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of common shares at the public offering price, less underwriting discounts and commissions.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Biohaven Pharmaceuticals Logo (PRNewsfoto/Biohaven Pharmaceutical Holding)

Goldman Sachs & Co. LLC and Piper Jaffray & Co. are acting as joint book-running managers of the offering.

The offering is being made only by means of a prospectus.  When available, copies of the prospectus related to the offering may be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com.

The shares will be issued pursuant to an effective shelf registration statement on Form S-3. Before investing in the offering, interested parties should read the prospectus and related prospectus supplement for this offering, the documents incorporated by reference therein and the other documents Biohaven has filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

Contact
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-proposed-public-offering-of-common-shares-300869887.html